Zevra Therapeutics (ZVRA) to Announce Quarterly Earnings on Wednesday

Zevra Therapeutics (NASDAQ:ZVRA) will likely be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Zevra Therapeutics to announce earnings of $0.08 per share and revenue of $33.8830 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%.The business had revenue of $36.22 million for the quarter, compared to the consensus estimate of $31.96 million. On average, analysts expect Zevra Therapeutics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Zevra Therapeutics Trading Down 1.8%

Shares of Zevra Therapeutics stock traded down $0.18 on Wednesday, hitting $9.55. 214,486 shares of the company traded hands, compared to its average volume of 1,355,924. Zevra Therapeutics has a 52 week low of $7.16 and a 52 week high of $15.03. The company has a market cap of $564.66 million, a PE ratio of 4.79 and a beta of 0.85. The stock’s 50 day moving average price is $12.35 and its 200-day moving average price is $10.50.

Wall Street Analysts Forecast Growth

ZVRA has been the subject of a number of research reports. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, June 9th. Canaccord Genuity Group reduced their price target on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Maxim Group upped their target price on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Zevra Therapeutics in a report on Tuesday, June 23rd. Nine investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $26.86.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. raised its stake in Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after acquiring an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares during the last quarter. Creative Planning acquired a new stake in shares of Zevra Therapeutics during the second quarter worth about $92,000. Qube Research & Technologies Ltd purchased a new stake in Zevra Therapeutics in the second quarter valued at approximately $99,000. Finally, Quarry LP acquired a new position in Zevra Therapeutics in the 3rd quarter worth approximately $103,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.